Comparison of Platelet Function Guided Versus Unguided Treatment With P2Y12 Inhibitors in Patients With Acute Myocardial Infarction (from the Hungarian Myocardial Infarction Registry)

• Published in: The American journal of cardiology Vol. 121; no. 10; pp. 1129 - 1137
• Main Authors: Komócsi, András, Aradi, Dániel, Szűk, Tibor, Nagy, Gergely György, Noori, Ebrahim, Ruzsa, Zoltán, Kiss, Róbert G., Andrássy, Péter, Nagy, Lajos, Nagy, Ferenc Tamás, Lupkovics, Géza, Kőszegi, Zsolt, Dézsi, Csaba András, Papp, Előd, Molnár, Zsolt, Kupó, Péter, Ofner, Péter, Merkely, Béla, Jánosi, András
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15-05-2018; Elsevier Limited
• Subjects: Aged; Blood platelets; Cardiology; Cause of Death; Clopidogrel; Clopidogrel - therapeutic use; Confidence intervals; Drug Substitution; Family medical history; Female; Heart attacks; Heart rate; Humans; Hungary; Inhibitors; Male; Matching; Middle Aged; Mortality; Myocardial infarction; Myocardial Infarction - therapy; Patients; Percutaneous Coronary Intervention; Platelet Function Tests; Platelets; Prasugrel Hydrochloride - therapeutic use; Propensity Score; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists - therapeutic use; Registries; Stroke; Treatment Outcome; Variables; Hungary
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2018.01.032

Evidence is conflicting regarding the clinical benefits of selecting P2Y12 inhibitors based on platelet function testing (PFT). Between March 1, 2013 and March 1, 2014, we collected clinical characteristics and platelet function data in a nationwide acute myocardial infarction (AMI) registry from 15 interventional cardiology centers in Hungary. The risk of all-cause mortality at 1 year were compared after propensity score (PS) matching between patients receiving PFT-guided and unguided P2Y12-inhibitor therapies. High platelet reactivity on clopidogrel (HPRoC) was uniformly defined with the Multiplate assay. A total of 5,583 patients with AMI and coronary intervention were registered. After exclusion of cases with contraindication to prasugrel, propensity matching resulted in a sample of 2,104 patients with well-adjusted characteristics. Clopidogrel was the dominant P2Y12 inhibitor in both groups (unguided: 96% vs PFT guided: 85%, p <0.001). In the PFT-guided group, 19% of patients had HPRoC and 77% of them were switched to prasugrel. According to the adjusted analysis, all-cause mortality at 1 year was significantly lower in the PFT-guided compared with the unguided group (hazard ratio 0.57 [95% confidence interval 0.43 to 0.77], p <0.001). Although prasugrel treatment was not associated with lower all-cause mortality in the overall cohort, patients with HPRoC who switched to prasugrel had significantly lower mortality when compared with those continuing clopidogrel (hazard ratio 0.33 [95% confidence interval 0.12 to 0.92], p <0.05). In conclusion, in patients with AMI, PFT-guided treatment with a high rate of switchover to prasugrel was associated with a lower risk of mortality. Prasugrel was a predictor of lower mortality in patients with HPRoC but not in the overall cohort of AMI.